Go alone - Risk Reward for TLN
Reward = 24.5 billions
Risk
Clinical risk
Dilution risk
Bankruptcy risk due to inability to raise capital
Oncology success is like a wild fire, speculator will jump in fast and furious.
Refinancing could be done later this year.
Desjardin, Dundee, Loewen group and Versant all cover TLN so there are many interested issuers.
If 4601 or 232 is a failure, there is always the 2 other application. SP could go back to 0,10$ based on technical support point.
At 0,20, no value is given to technologie.
Limited downside risk, that's why i keep on saying it.
Combining Financing and Partnership deal is probably the best strategy for Management.
Pivotal point for the company is now.
Timing to buy these shares is now - before PII trials.